Progyny, Inc. $PGNY Position Boosted by CenterBook Partners LP

CenterBook Partners LP grew its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 36.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 578,171 shares of the company’s stock after purchasing an additional 153,778 shares during the period. Progyny comprises approximately 0.7% of CenterBook Partners LP’s portfolio, making the stock its 26th biggest holding. CenterBook Partners LP’s holdings in Progyny were worth $14,847,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Federated Hermes Inc. boosted its position in shares of Progyny by 147.3% during the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock valued at $30,000 after purchasing an additional 819 shares in the last quarter. Hantz Financial Services Inc. boosted its holdings in shares of Progyny by 79.4% in the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after buying an additional 742 shares during the period. Quarry LP boosted its holdings in shares of Progyny by 2,004.1% in the third quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after buying an additional 3,427 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of Progyny in the second quarter worth about $77,000. Finally, New Age Alpha Advisors LLC acquired a new position in shares of Progyny in the fourth quarter worth about $94,000. Institutional investors own 94.93% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on PGNY shares. Bank of America raised their target price on shares of Progyny from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Progyny in a report on Friday, March 27th. Citigroup reiterated an “outperform” rating on shares of Progyny in a report on Monday, May 11th. Barclays raised their target price on shares of Progyny from $23.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Finally, KeyCorp decreased their target price on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Progyny presently has an average rating of “Moderate Buy” and an average target price of $29.67.

Progyny Price Performance

NASDAQ PGNY opened at $25.86 on Monday. The company has a 50 day simple moving average of $20.58 and a 200-day simple moving average of $22.26. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of 33.58, a price-to-earnings-growth ratio of 2.28 and a beta of 1.03. Progyny, Inc. has a 52-week low of $16.10 and a 52-week high of $28.75.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.24. The business had revenue of $328.50 million during the quarter, compared to analyst estimates of $326.47 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm’s revenue was down 26.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, analysts predict that Progyny, Inc. will post 1.07 EPS for the current year.

Progyny declared that its Board of Directors has authorized a stock repurchase plan on Tuesday, May 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to buy up to 10.3% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Insiders Place Their Bets

In other news, EVP Allison Swartz sold 1,199 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $25.02, for a total value of $29,998.98. Following the completion of the sale, the executive vice president directly owned 83,316 shares of the company’s stock, valued at $2,084,566.32. This represents a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 1,530 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total transaction of $39,137.40. Following the completion of the sale, the insider directly owned 59,117 shares of the company’s stock, valued at $1,512,212.86. This trade represents a 2.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 36,916 shares of company stock valued at $939,875 over the last ninety days. Insiders own 9.90% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.